Pier 88 Investment Partners LLC Acquires 292,370 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS)

Pier 88 Investment Partners LLC increased its holdings in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) by 296.6% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 390,960 shares of the company's stock after purchasing an additional 292,370 shares during the period. Pier 88 Investment Partners LLC owned approximately 0.63% of Pyxis Oncology worth $383,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. ProShare Advisors LLC acquired a new position in Pyxis Oncology in the 4th quarter valued at approximately $26,000. Caption Management LLC acquired a new position in Pyxis Oncology in the 4th quarter valued at approximately $35,000. Ameriprise Financial Inc. acquired a new position in Pyxis Oncology in the 4th quarter valued at approximately $35,000. Commonwealth Equity Services LLC raised its holdings in Pyxis Oncology by 61.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company's stock valued at $41,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Graham Capital Management L.P. acquired a new position in Pyxis Oncology in the 4th quarter valued at approximately $47,000. Institutional investors and hedge funds own 39.09% of the company's stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $5.00 price target on shares of Pyxis Oncology in a report on Monday, May 19th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Pyxis Oncology currently has a consensus rating of "Moderate Buy" and a consensus target price of $9.00.

Pyxis Oncology Stock Performance

Shares of PYXS stock traded down $0.08 during trading hours on Friday, hitting $1.27. The company had a trading volume of 470,836 shares, compared to its average volume of 568,013. Pyxis Oncology, Inc. has a 12 month low of $0.83 and a 12 month high of $5.39. The firm has a market capitalization of $78.37 million, a price-to-earnings ratio of -0.80 and a beta of 1.13. The firm's fifty day moving average is $1.20 and its 200 day moving average is $1.21.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.06). On average, sell-side analysts expect that Pyxis Oncology, Inc. will post -1.04 EPS for the current fiscal year.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.